Jazz Pharmaceuticals (NASDAQ: JAZZ) EVP Patil sells 55,600 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Jazz Pharmaceuticals EVP & Chief Legal Officer Neena M. Patil reported a mix of stock option exercises, share sales, and equity awards. She exercised multiple incentive and non-qualified stock options into ordinary shares and sold a total of 55,600 ordinary shares in open-market transactions at weighted average prices generally around $190–$193 per share. Patil also acquired 10,079 restricted stock units granted under the 2011 Equity Incentive Plan, which vest in equal annual installments over four years starting on March 5, 2026. Following these transactions, she directly owns 58,818 ordinary shares of Jazz Pharmaceuticals.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 55,600 shares ($10,650,482)
Net Sell
20 txns
Insider
Patil Neena M
Role
EVP & Chief Legal Officer
Sold
55,600 shs ($10.65M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Incentive Stock Option (right to buy) | 875 | $0.00 | -- |
| Exercise | Incentive Stock Option (right to buy) | 2,916 | $0.00 | -- |
| Exercise | Non-Qualified Stock Option (right to buy) | 20,125 | $0.00 | -- |
| Exercise | Non-Qualified Stock Option (right to buy) | 27,084 | $0.00 | -- |
| Exercise | Ordinary Shares | 20,125 | $113.10 | $2.28M |
| Sale | Ordinary Shares | 16,602 | $192.5271 | $3.20M |
| Exercise | Ordinary Shares | 875 | $113.10 | $99K |
| Sale | Ordinary Shares | 875 | $192.0651 | $168K |
| Exercise | Ordinary Shares | 27,084 | $137.12 | $3.71M |
| Sale | Ordinary Shares | 15,555 | $190.2801 | $2.96M |
| Exercise | Ordinary Shares | 2,916 | $137.12 | $400K |
| Sale | Ordinary Shares | 2,916 | $189.8117 | $553K |
| Grant/Award | Ordinary Shares | 10,079 | $0.00 | -- |
| Sale | Ordinary Shares | 11,529 | $191.6455 | $2.21M |
| Sale | Ordinary Shares | 3,523 | $193.5831 | $682K |
| Sale | Ordinary Shares | 1,061 | $190.0035 | $202K |
| Sale | Ordinary Shares | 549 | $190.7963 | $105K |
| Sale | Ordinary Shares | 1,784 | $191.8789 | $342K |
| Sale | Ordinary Shares | 1,009 | $192.7915 | $195K |
| Sale | Ordinary Shares | 197 | $193.5982 | $38K |
Holdings After Transaction:
Incentive Stock Option (right to buy) — 0 shares (Direct);
Non-Qualified Stock Option (right to buy) — 0 shares (Direct);
Ordinary Shares — 73,464 shares (Direct)
Footnotes (1)
- Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $192.1100 to $193.0100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $192.0600 to $192.1100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.9150 to $190.9000. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $189.7300 to $189.9150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $191.3200 to $192.0600. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $193.2900 to $193.8400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.395 to $190.3700. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $190.4100 to $191.2150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $191.4750 to $192.4300. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $192.4600 to $193.4500. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $193.5300 to $193.6700. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of July 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter.
FAQ
What insider transactions did Jazz Pharmaceuticals (JAZZ) report for Neena M. Patil?
Neena M. Patil reported exercising stock options, selling 55,600 ordinary shares, and receiving 10,079 restricted stock units. All transactions occurred on February 26, 2026, reflecting both liquidity sales and new equity incentives tied to her role at Jazz Pharmaceuticals.
What new equity awards did Neena Patil receive from Jazz Pharmaceuticals (JAZZ)?
Neena Patil received 10,079 restricted stock units representing rights to receive one ordinary share each upon vesting. These units were granted under Jazz’s 2011 Equity Incentive Plan and vest annually over four years starting on March 5, 2026, aligning compensation with long-term company performance.
Did Neena Patil exercise stock options in the latest Jazz Pharmaceuticals (JAZZ) Form 4?
Yes. The Form 4 shows Neena Patil exercising multiple incentive and non-qualified stock options into ordinary shares. These exercises were reported with transaction code “M,” which indicates the exercise or conversion of derivative securities into Jazz Pharmaceuticals ordinary shares.
How do Neena Patil’s restricted stock units in Jazz Pharmaceuticals (JAZZ) vest?
Neena Patil’s 10,079 restricted stock units vest in equal annual installments over four years starting on March 5, 2026. One quarter vests on the first anniversary, with the remaining units vesting in equal annual installments over the following three years, subject to plan terms.